Product image of Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide) supplied by GNH India

Mydrane

Active Ingredient:
Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide
Origin:
EU

Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine Hydrochloride, Phenylephrine Hydrochloride, Tropicamide, the active ingredients in Mydrane, are a combination ophthalmic anesthetic and mydriatic presented as an intracameral solution for intra‑ocular use. It provides rapid pupil dilation and local anesthesia during cataract surgery and other intra‑ocular procedures.

GNH India supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoires Thea

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mydrane is used in ophthalmic surgery to achieve rapid mydriasis and anesthesia.

  • Cataract surgery: provides pupil dilation and analgesia facilitating lens removal.
  • Intra‑ocular lens implantation: ensures adequate pupil size and patient comfort during lens placement.
  • Other intra‑ocular procedures: enables rapid mydriasis and local anesthesia for procedures such as trabeculectomy or vitrectomy.

How It Works

  • Lidocaine blocks voltage‑gated sodium channels in ocular nerves, producing local anesthesia. Phenylephrine, an α1‑adrenergic agonist, contracts the iris dilator muscle, while tropicamide, an antimuscarinic, relaxes the iris sphincter muscle. The combined actions result in swift pupil dilation and analgesia when administered intracamerally.

Side Effects

Mydrane may be associated with ocular and systemic adverse reactions following intracameral administration.

Common Side Effects

  • Transient ocular pain: mild discomfort after injection.
  • Redness of the eye: temporary conjunctival hyperemia.
  • Increased intra‑ocular pressure: short‑term rise detectable post‑procedure.
  • Blurred vision: temporary visual disturbance.
  • Light sensitivity: photophobia lasting a few hours.

Serious or Rare Side Effects

  • Allergic reaction: signs of hypersensitivity such as rash or swelling.
  • Persistent elevated intra‑ocular pressure: may require medical management.
  • Endophthalmitis: intra‑ocular infection, though rare.
  • Corneal edema: swelling affecting corneal clarity.

Precautions & Warnings

When using Mydrane, clinicians should consider several safety measures.

  • Patient assessment: evaluate for known hypersensitivity to lidocaine, phenylephrine, or tropicamide before use.
  • Cardiovascular status: use caution in patients with uncontrolled hypertension due to phenylephrine effects.
  • Ocular conditions: avoid in eyes with narrow-angle glaucoma or severe iris abnormalities.
  • Systemic disease: consider caution in patients with severe cardiac disease or arrhythmias.
  • Concomitant medications: review use of other mydriatics or adrenergic agents that may potentiate effects.
  • Store at ambient temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Mydrane can interact with other drugs, requiring attention to potential effects.

Major Interactions (Avoid)

  • Systemic phenylephrine: concurrent use may cause excessive vasoconstriction and hypertension.
  • Other topical mydriatics: combined use can lead to prolonged pupil dilation and increased intra‑ocular pressure.
  • MAO inhibitors: phenylephrine may potentiate hypertensive crisis.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may attenuate phenylephrine‑induced pupil dilation.
  • Anticholinergic drugs: additive mydriatic effect when combined with tropicamide.
  • Local anesthetics: overlapping sodium channel blockade may increase anesthetic depth.

Frequently Asked Questions

Mydrane is a combination ophthalmic anesthetic and mydriatic indicated for rapid pupil dilation and local anesthesia during cataract surgery and other intra‑ocular procedures. It is administered intracamerally to facilitate surgical access and improve patient comfort.

Lidocaine blocks voltage‑gated sodium channels in ocular nerves, producing local anesthesia. Phenylephrine, an α1‑adrenergic agonist, contracts the iris dilator muscle, while tropicamide, an antimuscarinic, relaxes the iris sphincter muscle. Together they achieve swift and sustained pupil dilation.

The dose of Mydrane is determined by the operating surgeon and depends on the specific procedure and patient factors. The prescribing information provides guidance, and the prescriber sets the appropriate volume to be injected intracamerally.

Safety data for Mydrane in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Mydrane, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Compared with single‑agent mydriatics, Mydrane combines a local anesthetic with two agents that act on different iris muscles, delivering faster and more complete dilation while also providing analgesia. This can reduce the need for separate anesthetic drops and shorten surgical preparation time.

Mydrane should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from light and moisture, and avoid freezing. Inspect the vial for particulate matter before use.

Mydrane is supplied as a sterile intracameral solution and is injected directly into the anterior chamber of the eye by the surgeon at the start of the procedure. The administration is performed under aseptic conditions in the operating theatre.

Serious risks include allergic reactions, persistent elevation of intra‑ocular pressure, endophthalmitis, and corneal edema. Prompt recognition and appropriate medical management are essential if any of these events occur.

Mydrane should be avoided in patients with known hypersensitivity to any of its components, uncontrolled hypertension, narrow‑angle glaucoma, severe cardiac disease, or those taking interacting medications that could exacerbate its effects. Clinical judgment should guide its use.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT